<DOC>
	<DOCNO>NCT01871441</DOCNO>
	<brief_summary>This phase II trial study well haploidentical donor hematopoietic stem cell transplant work treat patient hematologic malignancy . Giving chemotherapy total-body irradiation donor stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . Giving infusion donor 's T cell ( donor lymphocyte infusion ) may replace patient 's immune cell help destroy remain cancer cell . When stem cell related donor , closely match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet .</brief_summary>
	<brief_title>Haploidentical Donor Hematopoietic Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Examine 1 year disease free survival ( DFS ) rate patient maternal donor sibling donor share maternal haplotype ( maternal group ) compare patient receive cell donor point characteristic killer immunoglobulin-like receptor ( KIR ) ligand mismatching , minor histocompatibility antigen ( MHag ) difference , number human leukocyte antigen ( HLA ) mismatch ( non-maternal group ) . SECONDARY OBJECTIVES : I. Assess incidences relapse graft-versus-host disease ( GVHD ) maternal recipient whose eligible donor offspring . II . Assess incidence grade III-IV GVHD female recipient male donor . III . Compare rate DFS recipient-donor combination least 1 KIR ligand mismatch versus without KIR ligand mismatch . OUTLINE : Patients undergo total body irradiation ( TBI ) twice daily ( BID ) day -9 -6 , undergo donor lymphocyte infusion ( DLI ) day -6 , receive cyclophosphamide intravenously ( IV ) 2 hour day -3 -2 . TRANSPLANT : Patients undergo haploidentical allogeneic hematopoietic stem cell transplant day 0 . GVHD PROPHYLAXIS : Patients receive tacrolimus IV begin day -1 taper begin day 42 , mycophenolate mofetil IV BID day -1 day 28 . After completion study treatment , patient follow 90 , 180 , 270 day , 1 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Any patient hematologic oncologic diagnosis without morphological evidence disease allogeneic HSCT think beneficial . 2 . Patients must relate donor two allele mismatch HLAA ; B ; C ; DR locus . 3 . Patients must adequate organ function : 1 . LVEF ( Left ventricular ejection fraction ) &gt; 50 % 2 . Diffusion Capacity Carbon Monoxide ( DLCO ) &gt; 50 % predict correct hemoglobin 3 . Adequate liver function define serum bilirubin &lt; 1.8 , Aspartate Aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5X upper limit normal 4 . Creatinine clearance &gt; 60 ml/min 4 . Performance status &gt; 80 % ( TJU Karnofsky ) 5 . Hematopoietic Comorbidity Index ( HCTCI ) Score &lt; 5 Points 6 . Patients must willing use contraception childbearing potential 7 . Able give inform consent , decisionally impaired , legal next kin guardian give inform consent 1 . Performance status &lt; 80 % ( TJU Karnofsky ) 2 . HCTCI Score &gt; 5 Points 3 . Combination Performance status &lt; 80 % ( TJU Karnofsky ) HCTCI 4 point . 4 . HIV positive 5 . Active involvement central nervous system malignancy 6 . Psychiatric disorder would preclude patient sign informed consent 7 . Pregnancy 8 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder 9 . Patients receive alemtuzumab within 8 week transplant admission , recently receive horse rabbit antithymocyte globulin ATG level &gt; 2 ugm/ml 10 . Patients receive cyclophosphamide 11 . Patients evidence another malignancy , exclusive skin cancer require local treatment , enrol protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>